Wockhardt stock soars up to 16% as US FDA clears novel antibiotic Zaynich Shares of pharmaceutical company Wockhardt surged over 16% on Monday following the U.S. Food and Drug Administration’s (FDA) approval of its novel antibiotic Zaynich. The milestone marks a significant breakthrough for the company, which has invested years in developing a proprietary antibiotic research pipeline. The stock initially climbed as high as 16.21% at the opening trade but later settled at a 12.2% gain, trading at Rs 2,279 on the National Stock Exchange (NSE) at 9:42 am. Zaynich is designed to treat complicated urinary tract infections (cUTI), including pyelonephritis, and is specifically targeted at infections caused by drug-resistant Gram-negative bacteria. The FDA’s approval comes amid growing global concerns about antimicrobial resistance, which has limited treatment options for physicians. Wockhardt’s success in securing regulatory clearance in both the U.S. and India represents a rare achievement for an Indian pharmaceutical firm, as only a few companies have managed to navigate the complex process of developing globally relevant antibiotics. The approval is a culmination of Wockhardt’s long-term commitment to antibiotic research. The company has focused on addressing critical gaps in the market left by large global pharmaceutical firms that have reduced investments in antibiotic development. Zaynich’s target—Gram-negative resistant infections—represents one of the most challenging and rapidly evolving threats in infectious diseases. According to Wockhardt’s estimates, approximately two million patients worldwide suffer from such infections, creating a substantial market opportunity. The company projects a total addressable market for Zaynich of nearly $9 billion across the U.S., Europe, and India.#national_stock_exchange #ockhardt #us_fda #zaynich #dr_habil_khorakiwala
